{"schema_version":"secwatch.filing_event.v1","accession":"0001014739-22-000046","form_type":"8-K","ticker":"OPCH","cik":"0001014739","company_name":"Option Care Health, Inc.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.233784+00:00","generated_at":"2026-06-22T23:12:29.776621+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Option Care Health Q3 revenue up 14.5% to $1.02B; EPS $0.21; raises full-year guidance","bullets":["Net revenue $1,020.9M, up 14.5% YoY; gross margin 21.4% vs 22.8% in Q3 2021.","Net income $38.8M ($0.21 diluted EPS) vs $35.5M ($0.20) a year ago.","Adjusted EBITDA $85.6M (8.4% of revenue), up 9.8% from $78.0M.","FY2022 guidance: net revenue $3.90-3.95B, adj. EBITDA $336-341M, cash from ops ≥$250M.","Acquired Rochester Home Infusion for $27.4M in cash; cash balance $255.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001014739-22-000046","json":"https://secwatch.observer/filing/0001014739-22-000046.json","markdown":"https://secwatch.observer/filing/0001014739-22-000046.md","text":"https://secwatch.observer/filing/0001014739-22-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1014739/000101473922000046/0001014739-22-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1014739/000101473922000046/bios-20221027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:12:29.776621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd2fc804e40d8ff155ed1280d8e647ad78e87c35","claim":"Option Care Health, Inc. reported third quarter ended September 30, 2022 results: revenue $1,020.9 million, net income $38.8 million, or $0.21 per share, EPS $0.21 per share. Guidance raised.","evidence_excerpt":"and alternate site infusion services, today announced financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights • Net revenue of $1,020.9 million, up 14.5% compared to $891.9 million in the third quarter of 2021 • Gross profit of $218.0 million, or 21.4% of net revenue, up 7.4% compared to $203.0 million, or 22.8% of net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1014739/000101473922000046/0001014739-22-000046-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$1,020.9 million"},{"label":"Net income","value":"$38.8 million, or $0.21 per share"},{"label":"EPS","value":"$0.21 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}